Physician

Giselle Mery, M.D.

According to 2025 Medicare claims, Giselle Mery, M.D. (NPI: 1295747624) practices medical oncology in the Des Moines-West Des Moines, IA market, with the plurality of this provider's patient population coming from Polk, IA. This provider's primary affiliated billing organization is STATE UNIVERSITY OF IOWA (NPI: 1477554814; TIN: 426004813) and primary practice location at 50314-3030. Mery is affiliated with the Main Street Rural Health Willow ACO LLC (ACO ID: A5404) and CoreHealth Alliance LLC (ACO ID: A5645), participating under the MSSP model.

Mery's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 699 traditional Medicare patients, billed 171,976 HCPCS/CPT codes, and received $2,862,224 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 851 prescription claims across 139 beneficiaries totaling $1,091,257 in drug costs, led by Lenalidomide (Lenalidomide). DME data shows 65 claims. Open Payments data shows 3 records totaling $335. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $877,977 to $2,862,224. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $367,814 and ending at $1,091,257. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	526	86,353	$877,977
2016	431	90,374	$841,763
2017	380	84,787	$944,585
2018	418	85,761	$845,960
2019	417	86,049	$819,511
2020	339	82,873	$883,115
2021	364	55,113	$745,098
2022	240	47,462	$458,438
2023	530	99,375	$1,368,095
2024	699	171,976	$2,862,224

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	145	773	$367,814
2016	147	834	$481,863
2017	188	1,112	$810,455
2018	152	847	$1,083,598
2019	142	842	$1,479,530
2020	149	741	$943,478
2021	141	757	$578,465
2022	122	652	$915,881
2023	109	402	$314,958
2024	139	851	$1,091,257

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	13	$508
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	22	$5,339
2019	N/R	24	$2,979
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	41	$2,599
2024	N/R	65	$1,665

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	270	449	$89
96367	Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less	162	429	$20
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	217	364	$12
80053	Blood test, comprehensive group of blood chemicals	160	629	$10
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	171	920	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Lenalidomide	Lenalidomide	15	426	$185,811
Besremi	Ropeginterferon Alfa-2b-Njft	11	308	$174,151
Imbruvica	Ibrutinib	13	390	$133,971
Eliquis	Apixaban	43	1,572	$30,619
Xarelto	Rivaroxaban	25	909	$17,213

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	16	$565
J8700	Temozolomide, oral, 5 mg	N	N/R	13	$453
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	19	$358
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	17	$288

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	3	$335	Blueprint Medicines Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Giselle Mery, M.D.?

Tedicare shows public-source Medicare data for Giselle Mery, M.D. (NPI 1295747624), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Giselle Mery, M.D. have ACO affiliation data?

Giselle Mery, M.D. is shown with ACO affiliation data for Main Street Rural Health Willow ACO LLC (MSSP, ACO ID A5404) and CoreHealth Alliance LLC (MSSP, ACO ID A5645).

What billing organization is linked to Giselle Mery, M.D.?

Giselle Mery, M.D. is linked to STATE UNIVERSITY OF IOWA (billing NPI 1477554814) in the available physician profile data.

Does Giselle Mery, M.D. have Open Payments data?

Giselle Mery, M.D. has 3 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.